Pharming Group Faces Investor Scrutiny After Revenue Guidance Cut
A 22% plunge in Pharming Group’s stock price has triggered a securities investigation, following the company’s decision to slash its full-year revenue outlook by $30 million. The downward revision came less than three months after CEO Fabrice Chouraqui publicly reaffirmed the company's original growth targets to shareholders.


























